doi: 10.378-1844/14/07/468-08 25 ChakrabartiM.MukherjeeA
Vanhoof G, Goossens F, De Meester I, Hendriks D, Scharpe S
Market access and medical affairs teams to demonstrate the full value of these therapies
These divergent findings likely reflect heterogeneity in study design, mechanisms of action of the drugs evaluated, duration of follow-up, and the degree of metabolic phenotyping across populations
BPC157 (Bepecin, PL 14736), a small, chemically synthesised pentadecapeptide and a partial sequence of the human gastric juice protein BPC, which has been shown to be safe in clinical trials for inflammatory bowel disease and may be able to cure intestinal anastomosis dehiscence.
However, its important to note that while some patients may experience benefits, others might encounter side effects like digestive discomfort